List of Excipients in Branded Drug FLUDEOXYGLUCOSE F-18

Generic Drugs Containing FLUDEOXYGLUCOSE F-18

Company	Ingredient	NDC	Excipient
Lantheus Medical Imaging Inc	fludeoxyglucose f-18	11994-015	SODIUM CHLORIDE
Lantheus Medical Imaging Inc	fludeoxyglucose f-18	11994-015	TRISODIUM CITRATE DIHYDRATE
Lantheus Medical Imaging Inc	fludeoxyglucose f-18	11994-015	WATER
Pharmalogic South Carolina LLC	fludeoxyglucose f-18	16129-001	ALCOHOL
Pharmalogic South Carolina LLC	fludeoxyglucose f-18	16129-001	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in FLUDEOXYGLUCOSE F-18?

# Of NDCs	Excipient
4	ALCOHOL
1	CITRIC ACID MONOHYDRATE
1	DISODIUM CITRATE SESQUIHYDRATE
8	SODIUM CHLORIDE
4	SODIUM CITRATE

Fludeoxyglucose F-18 Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Fludeoxyglucose F-18, commonly called FDG or [18F]FDG, has a low-complexity formulation and limited opportunity for conventional excipient differentiation. The commercial value lies in excipient control, radiolysis mitigation, sterile manufacturing, container compatibility, and decentralized production support rather than in novel inactive ingredients. The dominant formulation is an aqueous, isotonic injectable containing FDG F-18, sodium chloride, and Water for Injection, generally without antimicrobial preservatives. Its 109.7-minute physical half-life makes supply-chain speed, validated production systems, and quality release more important than extended shelf life.[1][2]

What excipients are used in fludeoxyglucose F-18 injection?

Commercial FDG F-18 injections generally use a minimal excipient system:

Component	Primary function	Commercial relevance
Fludeoxyglucose F-18	Active diagnostic radiopharmaceutical	Short-lived positron-emitting glucose analog
Sodium chloride	Isotonicity adjustment and injectable vehicle	Standard, low-risk excipient
Water for Injection	Solvent	Must meet sterile pharmaceutical water requirements
Buffer, where used	pH control and radiolysis management	Product-specific; requires biodistribution and stability justification
Antioxidant, where used	Reduction of radiolytic degradation	Potentially useful but creates regulatory and impurity-control burdens
Nitrogen or other headspace control, where used	Reduction of oxygen-driven radiolysis	Manufacturing-process control rather than conventional formulation excipient

U.S. product labeling commonly identifies sodium chloride and Water for Injection and states that the injection contains no antimicrobial preservatives. Product specifications typically control pH, radiochemical identity, radiochemical purity, chemical purity, sterility, bacterial endotoxins, radionuclidic identity, and residual solvents.[1][3]

The preferred commercial strategy is usually a minimal formulation. Each additional excipient can affect glucose transporter behavior, tissue distribution, radiochemical purity, sterility validation, injectable tolerability, and regulatory comparability.

Why does the FDG F-18 formulation use few excipients?

FDG is administered in very small mass quantities, so the formulation does not require solubilizers, surfactants, suspending agents, or viscosity modifiers. The formulation objective is to deliver a sterile, injectable aqueous solution with acceptable osmolality and pH while preserving radiochemical purity during the product’s short usable period.

The key constraints are:

1. Short physical half-life. Fluorine-18 decays with a half-life of approximately 109.7 minutes. Every manufacturing or quality-control delay reduces the available activity.[2]

2. Radiolysis. High-energy radiation can generate reactive species that degrade FDG or create radiochemical impurities. The risk increases with activity concentration, storage time, oxygen exposure, temperature, and container surface interactions.

3. Glucose-like biodistribution. Excipients that alter glucose transport, insulin response, osmolality, or tissue metabolism can affect PET image interpretation.

4. Parenteral administration. The product must meet requirements for sterility, endotoxins, particulate matter, pH, and container closure integrity.

5. Small formulation window. A formulation must remain compatible with automated synthesis, sterile filtration, dispensing, dose calibration, and site-specific release testing.

A low-excipient formulation also simplifies manufacturing at commercial radiopharmacies and hospital-based PET drug facilities.

What is the strongest excipient strategy for FDG F-18?

The strongest strategy is a three-tier model: baseline saline formulation, targeted radiolysis control, and process-linked packaging control.

Tier 1: Standard isotonic saline formulation

The base product should use sodium chloride in Water for Injection unless a specific clinical or stability problem supports another composition. This approach offers:

• Familiar injectable excipient status.
• Straightforward toxicology.
• Low risk of altering biodistribution.
• Compatibility with PET drug manufacturing.
• Lower formulation complexity.
• Easier regulatory bridging to established FDG products.

A standard saline vehicle is unlikely to create meaningful composition-of-matter patent protection. Its value is operational reliability and broad regulatory acceptability.

Tier 2: Radiolysis-control formulation

Antioxidants or buffers may improve chemical stability, but they should be considered only when supported by activity-concentration and shelf-life data. Candidates may include ascorbate-based systems or other redox-active agents, but each candidate requires evaluation of:

• Chemical compatibility with FDG.
• Effect on radiochemical purity.
• Formation of radiolytic or degradation impurities.
• Injectable tolerability.
• Impact on pH and osmolality.
• Interference with analytical assays.
• Compatibility with sterile filtration.
• Effects on PET image quality or biodistribution.

A radiolysis-control excipient may have greater commercial value than sodium chloride because it can support longer release windows, higher activity concentrations, or lower wastage. The opportunity is strongest for centralized manufacturers shipping across larger geographic areas.

Tier 3: Oxygen and container control

Radiolysis mitigation does not depend only on the liquid formulation. Headspace oxygen, vial composition, stopper extractables, syringe materials, and surface adsorption can affect stability. Commercial products can differentiate through:

• Low-oxygen filling conditions.
• Nitrogen overlay or controlled headspace.
• Low-adsorption syringes.
• Radiation-compatible elastomers.
• Low-extractables vial and stopper systems.
• Validated multilayer containers.
• Automated dose-dispensing systems.

These controls may be protected more effectively through manufacturing know-how, device patents, and quality systems than through the excipient composition itself.

What formulation patents protect fludeoxyglucose F-18?

FDG is an established diagnostic agent with no practical opportunity for new basic composition patents covering the active molecule. Any historic composition or use patents would generally be expected to have expired or to provide little commercial blocking power.

Current protection is more likely to involve:

Protection category	Likely value
FDG active ingredient	Low; mature, well-known molecule
Saline or aqueous vehicle	Low; conventional excipient system
Buffer or antioxidant combination	Moderate if narrowly claimed and supported by stability data
Radiolysis-control process	Moderate to high if it improves shelf life or activity concentration
Automated synthesis cassette	Moderate; depends on claims and freedom to operate
Sterile dispensing and dose management	Moderate; commercially relevant for centralized production
Container closure and syringe system	Moderate; potential device and combination-product claims
Manufacturing method	Moderate; can create process differentiation
Method of use for PET imaging	Low to moderate; many established indications and competing methods
Hospital or radiopharmacy workflow	Usually protected by know-how rather than patents

A formulation patent would need to show more than the presence of a routine saline vehicle. Stronger claims could target a defined antioxidant concentration, oxygen-control condition, activity-concentration range, radiochemical purity threshold over a specified post-production interval, or container configuration. Enforceability would depend on whether the claimed formulation materially improves stability without compromising clinical performance.

How does FDA regulate FDG F-18 excipients and manufacturing?

FDG F-18 is regulated as a PET drug. FDA requirements include current good manufacturing practice and PET-specific controls under 21 C.F.R. Part 212. The product must meet controls for identity, strength, quality, purity, sterility, and labeling.[4]

FDA approval and manufacturing considerations include:

• Defined formulation and component specifications.
• Qualified suppliers for sodium chloride, Water for Injection, buffers, and antioxidants.
• Validation of sterile filtration and aseptic processing.
• Container closure integrity.
• Radiochemical and radionuclidic purity.
• Residual solvent controls from synthesis.
• Bacterial endotoxin testing.
• Stability data measured over the actual release and administration period.
• Assessment of excipient effects on biodistribution and image interpretation.
• Change-control procedures for radiopharmaceutical production sites.

PET drugs have a distinctive operational profile because release testing must occur before administration while radioactivity is decaying. Excipient changes that would be routine for a conventional injectable can require more extensive process validation for FDG because the available testing window is short.

What commercial opportunities exist in FDG F-18 excipients?

The largest opportunities are in supply reliability, radiolysis reduction, and production-site standardization.

Qualified excipient supply

Suppliers can provide pharmaceutical-grade sodium chloride, Water for Injection, buffers, antioxidants, and low-metal components in formats designed for radiopharmacy use. Value increases when the supplier offers:

• Small-batch sterile packaging.
• Rapid lot release.
• Low endotoxin limits.
• Radiopharmacy-compatible certificates of analysis.
• Lot-to-lot consistency.
• Single-use filling components.
• Regional inventory near PET production centers.

Commodity sodium chloride has limited margin potential. A qualified, presterilized excipient kit with documented radiopharmacy compatibility has greater commercial value.

Formulation kits for decentralized PET production

A ready-to-use formulation kit could combine sterile excipient solution, validated filters, reaction vessels, transfer lines, and dose containers. The commercial model would target hospital PET centers and smaller radiopharmacies that produce FDG on site.

Potential kit components include:

• Sterile saline or buffered vehicle.
• Prequalified antioxidant solution.
• Low-binding sterile filter.
• Validated sterile vial and stopper.
• Nitrogen-purged container.
• Batch record and release-test templates.

The kit would not eliminate the need for site-specific validation. Its value would be reduced production complexity and lower batch-to-batch variability.

Centralized manufacturing and extended distribution

A radiolysis-control formulation could support wider distribution from regional cyclotron facilities. The commercial benefit is measured through:

• Reduced activity loss before administration.
• Larger delivery radius.
• Fewer rejected or expired doses.
• Higher scanner utilization.
• Better alignment between production and appointment schedules.
• Lower dependence on same-site cyclotron infrastructure.

Because the physical half-life cannot be changed, formulation improvements create incremental value rather than conventional long-shelf-life economics.

Low-adsorption delivery systems

The dose may be supplied in a vial, syringe, or other dose-delivery format. A low-adsorption syringe or container can reduce residual activity and improve dose accuracy. Commercial claims can focus on:

• Delivered-dose accuracy.
• Reduced wall adsorption.
• Reduced residual volume.
• Automated dispensing compatibility.
• Radiation-resistant materials.
• Improved operator safety.

These products sit at the boundary between excipient strategy, packaging, and medical-device commercialization.

What are the main manufacturing and intellectual-property barriers?

The main barriers are operational rather than molecular.

Cyclotron and synthesis infrastructure

FDG requires a fluorine-18 production source, automated synthesis equipment, validated purification, sterile filtration, dispensing, and release testing. The short half-life limits the economic radius of distribution and makes local production capacity strategically important.

Quality-control release timing

A manufacturer must release product before activity falls below commercially useful levels. Methods that are slow, labor-intensive, or difficult to automate can reduce usable yield. Excipient suppliers that provide validated, ready-to-use materials can improve batch execution time.

Process and equipment freedom to operate

Potential IP issues can arise from:

• Automated synthesis modules.
• Cassette designs.
• Purification cartridges.
• Sterile dispensing systems.
• Dose-management software.
• Container and syringe systems.
• Radiolysis-control processes.

The mature FDG molecule itself is unlikely to create a blocking patent issue. Freedom-to-operate analysis should focus on equipment, consumables, process sequences, and packaging.

Site-specific validation

Even when an excipient is pharmacopeial grade, a change in supplier, concentration, packaging, or sterilization method can affect synthesis yield, filtration, stability, or release testing. This creates switching costs and supports supplier retention.

What is the patent and exclusivity outlook for FDG F-18?

FDG has no meaningful new-drug exclusivity profile comparable to a recently approved small molecule or biologic. The active ingredient is established, and generic or multisource supply is commercially available in multiple markets.

Issue	FDG F-18 outlook
New chemical entity exclusivity	Not applicable to this established agent
Orphan exclusivity	Generally not relevant to routine FDG PET use
Biosimilar risk	Not applicable; FDG is a small-molecule radiopharmaceutical
Basic composition patent	Historic or expired in practical commercial terms
Formulation patent	Possible only for narrow, differentiated systems
Method-of-use patent	Limited value for established PET indications
Paragraph IV risk	Relevant only if a new listed drug patent is asserted against a competing abbreviated or hybrid application
Orange Book leverage	Limited; product and patent listings depend on the specific approved application
Regulatory moat	More important than patent exclusivity
Manufacturing moat	High relative importance because of cyclotron access and validated production

The absence of strong active-ingredient exclusivity shifts value toward manufacturing reliability, geographic coverage, quality performance, and customer integration.

How does FDG compare with other PET radiopharmaceuticals?

FDG has the broadest commercial infrastructure among PET drugs, but its formulation differentiation is weaker than for newer agents.

Attribute	FDG F-18	Newer targeted PET agents
Active ingredient maturity	Very high	Often lower
Excipient complexity	Low	Variable
Formulation patent potential	Limited	Sometimes greater
Production infrastructure	Broad	More specialized
Distribution network	Established	Agent-dependent
Clinical use	Broad oncology, neurology, cardiology	Often narrower
Manufacturing moat	Cyclotron and process execution	May include ligand, precursor, generator, and synthesis IP
Biosimilar exposure	None	None for small-molecule PET drugs
Commercial differentiation	Reliability and cost	Clinical utility, targeting, and supply access

FDG’s competitive advantage is volume and familiarity. Its weakness is that standard formulation components are difficult to differentiate through patent claims.

What generic launch and commercial risks exist?

A new FDG supplier can generally compete through local production, pricing, delivery reliability, and customer service rather than through a novel excipient profile. The main risks are:

• Insufficient cyclotron uptime.
• Delayed delivery caused by traffic or production failure.
• Inadequate release-testing speed.
• Radiochemical purity failures.
• Sterility or endotoxin deviations.
• Container adsorption or dose-delivery loss.
• Inconsistent activity concentration.
• Excipient or packaging changes that require revalidation.
• Limited distribution radius.
• Reimbursement pressure on PET imaging providers.

For excipient companies, the primary risk is commoditization. A standard saline formulation produces limited pricing power. A validated radiolysis-control system or integrated formulation-and-container platform has a stronger commercial position.

Key Takeaways

• FDG F-18 is usually formulated as a sterile aqueous injection containing FDG, sodium chloride, and Water for Injection.
• The formulation is commonly preservative-free and uses few excipients.
• The highest-value technical problem is radiolysis control within a 109.7-minute half-life supply chain.
• Novel buffers or antioxidants may create commercial value, but they also introduce formulation, toxicology, analytical, and regulatory burdens.
• Container materials, oxygen control, sterile filtration, and dose-delivery systems may offer stronger differentiation than conventional excipients.
• FDG has limited active-ingredient patent leverage and no biosimilar pathway.
• Commercial barriers center on cyclotron access, automated synthesis, release testing, sterile production, distribution radius, and site validation.
• The best excipient opportunity is an integrated radiopharmacy platform that combines qualified sterile components, radiolysis control, validated packaging, and production workflow support.

FAQs About FDG F-18 Excipient Commercialization

Can an antioxidant create a new FDG F-18 patent position?

Yes, but only a narrowly defined antioxidant system with demonstrated stability, radiochemical, safety, and clinical-performance advantages is likely to support meaningful patent protection. A generic use of a known antioxidant is less defensible.

Does FDG F-18 require a preservative?

No. Commercial FDG injections are generally supplied without antimicrobial preservatives because they are sterile, single-use radiopharmaceutical products with short administration windows.[1]

Is sodium chloride essential to FDG F-18 formulation?

No. It is the conventional isotonicity-adjusting excipient, but alternative vehicles or buffers may be possible if they preserve stability, injectability, biodistribution, and product quality.

Can FDG excipients extend the product’s radioactive shelf life?

No excipient can extend fluorine-18’s physical half-life. Formulation and packaging controls can reduce chemical degradation and activity loss, allowing more efficient use of the remaining radioactivity.

Are FDG F-18 excipients subject to biosimilar competition?

No. FDG is a small-molecule radiopharmaceutical, not a biologic. Competitive entry occurs through approved radiopharmaceutical products and manufacturing sites rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (n.d.). Fludeoxyglucose F 18 injection prescribing information. DailyMed.

2. National Institute of Standards and Technology. (n.d.). Radionuclide half-life data: Fluorine-18. NIST.

3. United States Pharmacopeia. (2024). General chapter <823>: Positron emission tomography drugs for compounding, investigational, and research uses. United States Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 212: Current good manufacturing practice for positron emission tomography drugs. Code of Federal Regulations.